α發射體市場－全球產業規模、佔有率、趨勢、機會和預測：按放射性核種類型、醫療應用、地區和競爭格局分類，2021-2031年

全球α粒子發射材料市場預計將從2025年的4.7939億美元大幅成長至2031年的8.4234億美元，複合年成長率為9.85%。

該市場涉及α放射性核素的生產和應用，這些核素能夠精準靶向並摧毀癌細胞。推動這一市場成長的關鍵因素包括：對傳統治療方法抗藥性的轉移性癌症發生率不斷上升，以及α放射性核素相比現有放射線治療具有更優的臨床療效。隨著醫療專業人員尋求更有效的複雜癌症治療方法，這些因素持續推動著癌症治療領域對α放射性核種的需求。然而，儘管市場成長勢頭強勁，但仍面臨著許多挑戰，其中最主要的是由於依賴數量有限且老化的核子反應爐而導致的供應鏈不穩定。例如，根據《歐洲核子醫學》雜誌的報告，2024年，由於主要生產核子反應爐運作的意外延誤，全球範圍內出現了50%至100%的關鍵醫用同位素嚴重短缺。這種根本性的營運脆弱性極大地限制了該行業擴大生產規模以滿足不斷成長的全球需求的能力。

市場促進因素

策略合作正大幅擴大全球α放射性同位素市場，有效連結同位素生產與治療應用，並加強商業化進程。有鑑於此對業務永續營運的重要性，放射性藥物研發公司正日益積極地建立夥伴關係，以確保關鍵同位素（例如錒-225）的穩定供應鏈。一個顯著的例子是，NorthStar Medical Radioisotopes公司於2024年12月宣布與Ariceum Therapeutics公司達成供應協議，該協議將為臨床開發提供無載體錒-225，這表明該行業依賴戰略採購來緩解供不應求。此類合作關係對於確保材料供應和α射線療法的商業性可行性至關重要，而該行業強勁的財務表現也為其提供了支撐，例如Telix Pharmaceuticals公司2024年第四季未經審計的季度銷售額約為1.42億美元。同時，新型放射性配體臨床研發管線的擴展正在推動市場需求，加速標靶α射線療法（TAT）在癌症治療領域的發展。對α射線同位素日益成長的關注源於旨在推進專有候選藥物進入監管階段的大量資本投資。例如，Perspective Therapeutics公司在2025年3月報告稱，其擁有約2.27億美元的現金儲備，足以支持營運和臨床試驗直至2026年底，這凸顯了將這些複雜治療方法推向市場所需的巨額投資。此類專款將加速先進治療方法（包括基於鉛-212的療法）的開發，從而擴大受益患者群體，並促進α發射同位素在精準腫瘤學中的更廣泛應用。

市場挑戰

全球α放射性核種市場的成長受到關鍵供應鏈可靠性問題的嚴重限制，而這些問題主要源自於對老舊核能基礎設施的依賴。 α放射性核子反應爐，這些反應器極易發生機械故障和計劃外維護。由於這些核子反應爐半衰期短且難以儲存，即使單一設施發生輕微運作，也可能立即引發全球供不應求​​。這種結構性不穩定迫使醫療機構推遲或停止關鍵的癌症治療，從而削弱臨床信心，並增加新治療方法開發商的商業化風險。生產設施的老化進一步凸顯了供應鏈固有的結構性脆弱性。 《歐洲核子醫學》2024年的報告指出，全球六大主要醫用同位素供應高功率核子反應爐中，有五座已運作超過50年。依賴少數幾座遠超設計壽命的設施造成了嚴重的瓶頸，嚴重阻礙了市場擴張。因此，無法保證穩定且擴充性的供應，直接阻礙了該行業滿足腫瘤學領域對標靶α療法快速成長的需求的能力。

市場趨勢

基於加速器的生產技術的商業化正在顯著改變市場上的上游供應鏈，減少對老舊核子反應爐的依賴。這項技術進步使得利用電子加速器和迴旋加速器實現錒-225等關鍵同位素的擴充性區域化生產成為可能。這種方法有效降低了核子反應爐維護問題和地緣政治不穩定造成的供應中斷風險。主要產業相關人員正在大力投資這種生產方法，以建立穩健的商業級庫存，用於未來的治療方法，從而擺脫對脆弱的科學研究核子反應爐網路的依賴。例如，PanTera公司於2024年9月宣布已獲得9,300萬歐元的A輪資金籌措，用於在比利時建立大型生產設施。該公司計劃在2029年每年生產超過100居里的錒-225，以滿足全球需求。同時，將α發射同位素整合到治療診斷學（治療與診斷的融合）中，透過將精確的診斷成像與目標細胞的破壞相結合，正在加速市場應用。此方法利用放射性雜合物或互補配體在治療前可視化腫瘤受體表達，從而最佳化患者篩選並增強α發射同位素的治療效果。開發人員正在資金籌措以推進這些雙用途平台的發展，凸顯了「可視化和治療」模式的臨床價值，該模式相比單一用途療法具有更高的精確度。例如，2024年10月，Blue Earth Therapeutics公司獲得了7,650萬美元的A輪資金籌措，用於加速其下一代放射性配體產品線的開發，其中包括用於前列腺癌治療的α發射血清學候選化合物225Ac-rhPSMA-10.1。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球α發射體市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 放射性核種（砹（At-211）、鐳（Ra-223）、錒（Ac-225）、鉛（Pb-212）、鉍（Bi-212）、其他）
  • 用於醫療用途（前列腺癌、骨轉移、卵巢癌、胰臟癌、內分泌腫瘤等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美α發射體市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲α發射體市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區α發射體市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲α發射體的市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲阿爾法α發射體的市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球α發射體市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Actinium Pharmaceutical Inc.
• Alpha Tau Medical Ltd
• Bayer AG
• Fusion Pharmaceuticals Inc.
• Ion Beam Applications SA
• RadioMedix Inc.
• Telix Pharmaceuticals Ltd
• Novartis International AG
• Isotopen Technologien Munchen AG
• NorthStar Medical Radioisotopes LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

The global alpha emitter market is projected to expand significantly, growing from USD 479.39 million in 2025 to USD 842.34 million by 2031, demonstrating a compound annual growth rate of 9.85%. This market involves the creation and use of radionuclides that release alpha particles, which precisely target and eliminate tumor cells. Key factors propelling this growth include the rising incidence of metastatic cancers that are resistant to conventional treatments and the superior clinical effectiveness of alpha emitters compared to existing radiation therapies. These elements continuously drive the need for alpha emitters in cancer care, as medical professionals seek more potent interventions for intricate cancers.However, despite this strong growth trajectory, the market contends with a critical obstacle: the unreliability of its supply chain, stemming from its reliance on a limited number of aging nuclear reactors. In 2024, for instance, unforeseen delays in reactivating a significant production reactor led to severe shortages, ranging from 50% to 100%, of essential medical isotopes across various global regions, as reported by Nuclear Medicine Europe. This inherent operational fragility severely limits the industry's capacity to increase production in line with escalating global demand.

Market Driver

Strategic collaborations are significantly boosting the global alpha emitter market by effectively connecting isotope production with therapeutic applications, thereby strengthening commercialization efforts. Radiopharmaceutical developers are increasingly forming partnerships to secure stable supply chains for vital isotopes, such as Actinium-225, recognizing their importance for operational continuity. A notable example is NorthStar Medical Radioisotopes' December 2024 announcement of a supply agreement with Ariceum Therapeutics, demonstrating the industry's reliance on strategic sourcing to alleviate scarcity by providing non-carrier-added Actinium-225 for clinical development. These alliances are crucial for ensuring material availability and confirming the commercial viability of alpha therapies, supported by robust financial performance within the sector, as illustrated by Telix Pharmaceuticals' unaudited quarterly revenue of around $142 million in Q4 2024.Concurrently, the expansion of clinical pipelines for novel radioligands is fueling market demand as companies expedite the creation of targeted alpha therapies (TAT) for cancer. The heightened focus on alpha-emitting isotopes is underpinned by substantial capital investments aimed at progressing proprietary drug candidates through regulatory stages. For instance, Perspective Therapeutics reported in March 2025 a cash reserve of approximately $227 million, intended to finance operations and clinical trials until late 2026, highlighting the considerable investment needed to introduce these intricate therapies to the market. Such dedicated funding accelerates the development of advanced treatments, including those based on Lead-212, consequently broadening the patient population that can benefit and promoting the wider adoption of alpha emitters in precision oncology.

Market Challenge

The global alpha emitter market's growth is severely hindered by the critical issue of supply chain reliability, primarily due to its dependence on an aging nuclear infrastructure. The manufacturing of alpha-emitting radionuclides relies extensively on a legacy fleet of research reactors, which are increasingly susceptible to mechanical breakdowns and unscheduled maintenance. Given the short half-lives of these isotopes, preventing their stockpiling, even slight operational interruptions at a single facility can trigger immediate, worldwide shortages. This inherent instability compels healthcare providers to postpone or cancel crucial cancer treatments, diminishing clinical trust and elevating the commercialization risk for developers introducing new therapies.The inherent structural vulnerability of the supply network is underscored by the advanced age of its production facilities. As reported by Nuclear Medicine Europe in 2024, five out of the six primary high-flux reactors responsible for supplying medical isotopes globally were more than 50 years old. This reliance on a small number of facilities, operating significantly past their intended design lives, creates a critical bottleneck that actively impedes market expansion. Consequently, the inability to guarantee a steady, scalable supply directly obstructs the industry's capacity to satisfy the rapidly increasing demand for targeted alpha therapies in oncology.

Market Trends

The commercialization of accelerator-based production technologies is profoundly transforming the upstream supply chain of the market by decreasing its dependence on aging nuclear reactors. This technological evolution facilitates the scalable and regional production of vital isotopes, such as Actinium-225, utilizing electron accelerators and cyclotrons. This approach effectively lessens the risks of supply disruptions caused by reactor maintenance issues or geopolitical instability. Key industry participants are heavily investing in this production method to build robust, commercial-grade inventories for future therapies, shifting away from the vulnerable network of academic reactors. For example, PanTera announced in September 2024 that it secured EUR 93 million in Series A funding to establish a large-scale production facility in Belgium, aiming to produce over 100 Curies of Actinium-225 annually by 2029 to satisfy global demand.Simultaneously, the integration of alpha emitters into theranostic pairings is accelerating market adoption by merging precise diagnostic imaging with targeted cell destruction. This approach employs radiohybrid or complementary ligands to visualize tumor receptor expression prior to treatment, thereby improving patient selection and enhancing the therapeutic effectiveness of alpha-emitting isotopes. Developers are obtaining substantial funding to advance these dual-purpose platforms, thereby confirming the clinical value of "see and treat" models, which offer superior accuracy compared to single-purpose therapeutic agents. Blue Earth Therapeutics, for instance, secured $76.5 million in Series A financing in October 2024 to expedite the development of its next-generation radioligand pipeline, which includes the alpha-emitting theranostic candidate 225Ac-rhPSMA-10.1 for treating prostate cancer.

Key Market Players

• Actinium Pharmaceutical Inc.
• Alpha Tau Medical Ltd
• Bayer AG
• Fusion Pharmaceuticals Inc.
• Ion Beam Applications S.A.
• RadioMedix Inc.
• Telix Pharmaceuticals Ltd
• Novartis International AG
• Isotopen Technologien Munchen AG
• NorthStar Medical Radioisotopes LLC

Report Scope

In this report, the Global Alpha Emitter Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alpha Emitter Market, By Type of Radionuclide

• Astatine (At-211)
• Radium (Ra-223)
• Actinium (Ac-225)
• Lead (Pb-212)
• Bismuth (Bi-212)
• Other

Alpha Emitter Market, By Medical Application

• Prostate Cancer
• Bone Metastasis
• Ovarian Cancer
• Pancreatic Cancer
• Endocrine Tumors
• Other

Alpha Emitter Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alpha Emitter Market.

Available Customizations:

Global Alpha Emitter Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alpha Emitter Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Radionuclide (Astatine (At-211), Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212), Bismuth (Bi-212), Other)
  • 5.2.2. By Medical Application (Prostate Cancer, Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Alpha Emitter Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Radionuclide
  • 6.2.2. By Medical Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Alpha Emitter Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Radionuclide
      • 6.3.1.2.2. By Medical Application
  • 6.3.2. Canada Alpha Emitter Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Radionuclide
      • 6.3.2.2.2. By Medical Application
  • 6.3.3. Mexico Alpha Emitter Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Radionuclide
      • 6.3.3.2.2. By Medical Application

7. Europe Alpha Emitter Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Radionuclide
  • 7.2.2. By Medical Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Alpha Emitter Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Radionuclide
      • 7.3.1.2.2. By Medical Application
  • 7.3.2. France Alpha Emitter Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Radionuclide
      • 7.3.2.2.2. By Medical Application
  • 7.3.3. United Kingdom Alpha Emitter Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Radionuclide
      • 7.3.3.2.2. By Medical Application
  • 7.3.4. Italy Alpha Emitter Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Radionuclide
      • 7.3.4.2.2. By Medical Application
  • 7.3.5. Spain Alpha Emitter Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Radionuclide
      • 7.3.5.2.2. By Medical Application

8. Asia Pacific Alpha Emitter Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Radionuclide
  • 8.2.2. By Medical Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Alpha Emitter Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Radionuclide
      • 8.3.1.2.2. By Medical Application
  • 8.3.2. India Alpha Emitter Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Radionuclide
      • 8.3.2.2.2. By Medical Application
  • 8.3.3. Japan Alpha Emitter Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Radionuclide
      • 8.3.3.2.2. By Medical Application
  • 8.3.4. South Korea Alpha Emitter Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Radionuclide
      • 8.3.4.2.2. By Medical Application
  • 8.3.5. Australia Alpha Emitter Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Radionuclide
      • 8.3.5.2.2. By Medical Application

9. Middle East & Africa Alpha Emitter Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Radionuclide
  • 9.2.2. By Medical Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Alpha Emitter Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Radionuclide
      • 9.3.1.2.2. By Medical Application
  • 9.3.2. UAE Alpha Emitter Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Radionuclide
      • 9.3.2.2.2. By Medical Application
  • 9.3.3. South Africa Alpha Emitter Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Radionuclide
      • 9.3.3.2.2. By Medical Application

10. South America Alpha Emitter Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Radionuclide
  • 10.2.2. By Medical Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Alpha Emitter Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Radionuclide
      • 10.3.1.2.2. By Medical Application
  • 10.3.2. Colombia Alpha Emitter Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Radionuclide
      • 10.3.2.2.2. By Medical Application
  • 10.3.3. Argentina Alpha Emitter Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Radionuclide
      • 10.3.3.2.2. By Medical Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Alpha Emitter Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Actinium Pharmaceutical Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Alpha Tau Medical Ltd
• 15.3. Bayer AG
• 15.4. Fusion Pharmaceuticals Inc.
• 15.5. Ion Beam Applications S.A.
• 15.6. RadioMedix Inc.
• 15.7. Telix Pharmaceuticals Ltd
• 15.8. Novartis International AG
• 15.9. Isotopen Technologien Munchen AG
• 15.10. NorthStar Medical Radioisotopes LLC

16. Strategic Recommendations

17. About Us & Disclaimer